Optomed (OPTOMED) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue grew 39.3% year-over-year to EUR 5.1 million, driven by a large US Devices order; full-year revenue was stable at EUR 15.0 million.

• Devices segment revenue surged nearly 150% in Q4, while Software segment declined 3.3% due to slower contract renewals.

• Positive net cash flow from operating activities in Q4 and a strong year-end cash position of EUR 10.5 million.

• FDA clearance for Aurora AEYE-DS AI in Q2 2024 enables US market expansion and supports 2025 growth.

• A joint venture was established in China in Q2 2024; a directed share issue in Q2 raised EUR 7.9 million gross proceeds.

Financial highlights

• Q4 2024 revenue: EUR 5.1 million (+39.3% YoY); full-year 2024: EUR 15.0 million (-0.4% YoY).

• Q4 gross margin: 65.1% (vs. 68.0%); full-year gross margin: 64.3% (vs. 68.2%).

• Q4 Adjusted EBITDA: EUR -0.5 million (margin -10.4%); full-year Adjusted EBITDA: EUR -2.8 million (margin -18.6%).

• Q4 net loss: EUR -1.0 million (vs. -1.5 million); full-year net loss: EUR -5.5 million (vs. -4.4 million).

• Cash and cash equivalents at year-end: EUR 10.5 million (vs. 7.1 million); net debt: EUR -8.2 million.

Outlook and guidance

• Strong revenue growth expected for 2025, driven by US FDA clearance, new partnerships, and continued AI innovation.

• Cost trajectory expected to remain similar to 2024, with flexibility for increased marketing if needed.

• Software segment growth expected to be modest, with China remaining uncertain.

• Key uncertainties include timing and size of large deals, market dynamics, and geopolitical factors.